KR102643821B1 - 익상편을 치료하기 위한 조성물 및 방법 - Google Patents

익상편을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102643821B1
KR102643821B1 KR1020187000359A KR20187000359A KR102643821B1 KR 102643821 B1 KR102643821 B1 KR 102643821B1 KR 1020187000359 A KR1020187000359 A KR 1020187000359A KR 20187000359 A KR20187000359 A KR 20187000359A KR 102643821 B1 KR102643821 B1 KR 102643821B1
Authority
KR
South Korea
Prior art keywords
pterygium
delete delete
nintedanib
formulation
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187000359A
Other languages
English (en)
Korean (ko)
Other versions
KR20180030499A (ko
Inventor
진송 니
Original Assignee
클라우드브레이크 테라퓨틱스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57504837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102643821(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 클라우드브레이크 테라퓨틱스, 엘엘씨 filed Critical 클라우드브레이크 테라퓨틱스, 엘엘씨
Priority to KR1020247006976A priority Critical patent/KR20240034866A/ko
Publication of KR20180030499A publication Critical patent/KR20180030499A/ko
Application granted granted Critical
Publication of KR102643821B1 publication Critical patent/KR102643821B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020187000359A 2015-06-06 2016-06-03 익상편을 치료하기 위한 조성물 및 방법 Active KR102643821B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247006976A KR20240034866A (ko) 2015-06-06 2016-06-03 익상편을 치료하기 위한 조성물 및 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562172063P 2015-06-06 2015-06-06
US62/172,063 2015-06-06
US201562186660P 2015-06-30 2015-06-30
US62/186,660 2015-06-30
PCT/US2016/035726 WO2016200688A1 (en) 2015-06-06 2016-06-03 Compositions and methods for treating pterygium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247006976A Division KR20240034866A (ko) 2015-06-06 2016-06-03 익상편을 치료하기 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20180030499A KR20180030499A (ko) 2018-03-23
KR102643821B1 true KR102643821B1 (ko) 2024-03-07

Family

ID=57504837

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020187000359A Active KR102643821B1 (ko) 2015-06-06 2016-06-03 익상편을 치료하기 위한 조성물 및 방법
KR1020247006976A Ceased KR20240034866A (ko) 2015-06-06 2016-06-03 익상편을 치료하기 위한 조성물 및 방법
KR1020267004435A Pending KR20260025887A (ko) 2015-06-06 2016-06-03 익상편을 치료하기 위한 조성물 및 방법
KR1020247010160A Active KR102906248B1 (ko) 2015-06-06 2016-06-03 익상편을 치료하기 위한 조성물 및 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020247006976A Ceased KR20240034866A (ko) 2015-06-06 2016-06-03 익상편을 치료하기 위한 조성물 및 방법
KR1020267004435A Pending KR20260025887A (ko) 2015-06-06 2016-06-03 익상편을 치료하기 위한 조성물 및 방법
KR1020247010160A Active KR102906248B1 (ko) 2015-06-06 2016-06-03 익상편을 치료하기 위한 조성물 및 방법

Country Status (10)

Country Link
US (7) US9980901B2 (https=)
EP (2) EP3302379B1 (https=)
JP (5) JP6868014B2 (https=)
KR (4) KR102643821B1 (https=)
CN (2) CN108135737B (https=)
AU (3) AU2016276170B2 (https=)
ES (1) ES2971096T3 (https=)
MX (2) MX393691B (https=)
TW (1) TWI714596B (https=)
WO (1) WO2016200688A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102643821B1 (ko) 2015-06-06 2024-03-07 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
TWI700085B (zh) * 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
KR102657707B1 (ko) 2016-06-02 2024-04-15 에이디에스 테라퓨틱스 엘엘씨 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법
US11278546B2 (en) 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
JP7018939B2 (ja) * 2016-09-26 2022-02-14 ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US10335313B2 (en) * 2017-08-16 2019-07-02 Brian S. Boxer Wachler Method for removing colored spots to whiten the eye
US20200345637A1 (en) * 2018-01-19 2020-11-05 Aiviva Biopharma, Inc. Suspension compositions of multi-target inhibitors
US20190346048A1 (en) 2018-05-11 2019-11-14 Quarter Turn Pressure Control, LLC Replaceable body saver
CA3099789A1 (en) * 2018-05-25 2019-11-28 Cloudbreak Therapeutics Llc A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
US10941902B2 (en) 2018-07-10 2021-03-09 Quarter Turn Pressure Control, LLC Valve grease blocks for high pressure valves and high pressure valves using the same
AU2019321429B2 (en) * 2018-08-15 2022-12-08 Aiviva Biopharma, Inc. Multi-kinase inhibitors of VEGF and TGF beta and uses thereof
EP4349327A3 (en) * 2018-08-28 2024-07-24 Cloudbreak Therapeutics, LLC Emulsion formulations of multikinase inhibitors
US10744153B1 (en) * 2019-07-01 2020-08-18 Cloudbreak Therapeutics Llc Compositions and methods for treating meibomian gland dysfunction
BR112021026662A2 (pt) * 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho
WO2021165369A1 (en) * 2020-02-19 2021-08-26 Vestlandets Innovasjonsselskap As Treatment of corneal vascularisation
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
JP2023527884A (ja) * 2020-06-01 2023-06-30 エーディーエス・セラピューティクス・エルエルシー 異常な血管新生を治療するための局所眼科用組成物および方法
EP4346720A4 (en) 2021-05-28 2025-01-01 Sight Sciences, Inc. INTRAOCULAR DEVICES, SYSTEMS AND METHODS
CN113425728A (zh) * 2021-06-29 2021-09-24 复旦大学附属眼耳鼻喉科医院 一种zd6474在翼状胬肉术后抗复发的治疗药物制备中的应用
JP2025525881A (ja) * 2022-08-16 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼内使用するためのニンテダニブの医薬製剤
AU2022488910A1 (en) * 2022-12-13 2025-06-19 Suzhou Raymon Pharmaceuticals Company, Ltd. Use of naphthylurea compounds in preparation of drugs for treating pterygium
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物
USD1120038S1 (en) * 2023-11-30 2026-03-24 J. C. Bamford Excavators Limited Part of an excavator arm

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186336A1 (en) 2012-12-28 2014-07-03 Randal Tanh Hoang Pham Methods of treating pterygium

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739271B2 (en) * 1997-02-14 2001-10-11 Kissei Pharmaceutical Co. Ltd. Agents inhibiting progress of pterygium and postoperative recurrence of the same
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
EP2803357B1 (en) * 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesis inhibitors
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20080003219A1 (en) * 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US8558002B2 (en) * 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
RU2518898C2 (ru) 2007-04-05 2014-06-10 Пфайзер Продактс Инк. Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у млекопитаюших
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
RU2351298C1 (ru) 2007-11-27 2009-04-10 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ профилактики рецидива птеригиума
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
MX2010013203A (es) 2008-06-06 2011-02-25 Boehringer Ingelheim Int Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona.
US20100185564A1 (en) 2009-01-21 2010-07-22 Mccormick & Company, Inc. Method and questionnaire for measuring consumer emotions associated with products
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
TW201201808A (en) * 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
EP3085358B1 (en) * 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
CN102018686B (zh) * 2010-12-16 2012-12-05 浙江大学医学院附属邵逸夫医院 含有丝裂霉素的膜剂及其制备方法
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
WO2013000909A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
KR20140048218A (ko) * 2011-06-28 2014-04-23 바이엘 헬스케어 엘엘씨 레고라페닙을 함유하는 국소 안과용 약학 조성물
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
EP2802314B1 (en) 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
CN107115294B (zh) * 2012-01-19 2019-10-18 北京康弘生物医药有限公司 一种含有vegf拮抗剂的滴眼液
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
NZ742005A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
EP2863885A1 (en) * 2012-06-25 2015-04-29 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing cediranib
EP2863888A1 (en) * 2012-06-25 2015-04-29 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing axitinib
HK1204992A1 (en) * 2012-06-25 2015-12-11 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
US20150141448A1 (en) 2012-06-25 2015-05-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Pazopanib
US10238536B2 (en) 2012-10-11 2019-03-26 The Regents Of The University Of Colorado, A Body Corporate Ocular filtration devices, systems and methods
EP2916827B1 (en) 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
WO2014158863A1 (en) * 2013-03-14 2014-10-02 Massachusetts Eye And Ear Infirmary Conjunctival diseases
ES2834964T3 (es) * 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
SG10201702674PA (en) * 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
US20140378401A1 (en) 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
US10010610B2 (en) 2014-01-16 2018-07-03 Retinal Therapies, LLC Compositions and methods for the treatment of intraocular neovascularization and/or leakage
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
CN104448300B (zh) * 2014-12-09 2017-01-11 西安医学院 低分子量l-聚谷氨酸-丝裂霉素c及其合成方法和应用
WO2016123152A1 (en) 2015-01-26 2016-08-04 University Of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
KR102643821B1 (ko) * 2015-06-06 2024-03-07 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
EP3692991A1 (de) 2015-06-09 2020-08-12 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
TWI700085B (zh) 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
WO2017015591A1 (en) 2015-07-22 2017-01-26 Incept, Llc Coated punctal plug
CN108602879A (zh) 2016-02-04 2018-09-28 倪劲松 用于治疗疾病的抗体-药物协同作用技术
KR102657707B1 (ko) 2016-06-02 2024-04-15 에이디에스 테라퓨틱스 엘엘씨 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법
US11278546B2 (en) 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
JP7018939B2 (ja) 2016-09-26 2022-02-14 ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
CN110072849A (zh) 2017-03-14 2019-07-30 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
CA3099789A1 (en) 2018-05-25 2019-11-28 Cloudbreak Therapeutics Llc A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
CN110664757B (zh) 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 纳米晶滴眼剂、其制备方法及其应用
BR112021026662A2 (pt) 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho
WO2021168218A1 (en) 2020-02-19 2021-08-26 Clearside Biomedical, Inc. Compositions comprising axitinib and methods of treating ocular disorders
CN116251186B (zh) 2021-12-09 2025-04-25 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186336A1 (en) 2012-12-28 2014-07-03 Randal Tanh Hoang Pham Methods of treating pterygium

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clinical Ophthalmology, 6, 1849-1854, 2012.
Invet. Ophthazlmol. Vis. Sci., 54(1), 537-544, 2013.
Rom. J. Morphol. Enbryol., 52(3), 837-844, 2011.

Also Published As

Publication number Publication date
US20180271780A1 (en) 2018-09-27
JP2025094111A (ja) 2025-06-24
JP2023062133A (ja) 2023-05-02
HK1253895A1 (en) 2019-07-05
TWI714596B (zh) 2021-01-01
EP3302379A1 (en) 2018-04-11
EP4335418A2 (en) 2024-03-13
AU2024200946A1 (en) 2024-02-29
AU2021218212A1 (en) 2021-09-09
AU2016276170A1 (en) 2017-12-14
EP4335418A3 (en) 2024-05-22
US20190110984A1 (en) 2019-04-18
MX2017015838A (es) 2018-08-15
KR20240043821A (ko) 2024-04-03
TW201709910A (zh) 2017-03-16
US10149820B2 (en) 2018-12-11
JP7571171B2 (ja) 2024-10-22
EP3302379B1 (en) 2023-11-22
CN108135737B (zh) 2021-11-05
US10149819B2 (en) 2018-12-11
US10980741B2 (en) 2021-04-20
BR112017025122A2 (pt) 2018-07-31
US20210308042A1 (en) 2021-10-07
MX393691B (es) 2025-03-24
ES2971096T3 (es) 2024-06-03
AU2021218212B2 (en) 2023-11-16
JP7234283B2 (ja) 2023-03-07
WO2016200688A1 (en) 2016-12-15
JP2024069363A (ja) 2024-05-21
US9987223B2 (en) 2018-06-05
US12186424B2 (en) 2025-01-07
AU2024200946B2 (en) 2026-03-26
EP3302379A4 (en) 2019-01-23
US20180271781A1 (en) 2018-09-27
CA2988293A1 (en) 2016-12-15
KR20240034866A (ko) 2024-03-14
KR102906248B1 (ko) 2026-01-02
JP7774170B2 (ja) 2025-11-20
US20170172915A1 (en) 2017-06-22
CN114010787A (zh) 2022-02-08
US20170209368A1 (en) 2017-07-27
JP7838007B2 (ja) 2026-03-31
US9980901B2 (en) 2018-05-29
KR20180030499A (ko) 2018-03-23
AU2016276170B2 (en) 2021-08-05
CN108135737A (zh) 2018-06-08
JP2018521120A (ja) 2018-08-02
JP6868014B2 (ja) 2021-05-12
MX2022007989A (es) 2022-07-21
JP2021113201A (ja) 2021-08-05
US20250262148A1 (en) 2025-08-21
HK1256602A1 (zh) 2019-09-27
KR20260025887A (ko) 2026-02-24

Similar Documents

Publication Publication Date Title
JP7774170B2 (ja) 翼状片を治療するための組成物及び方法
HK40069641A (en) Compositions and methods for treating pterygium
CA2988293C (en) Compositions and methods for treating pterygium
HK40101374A (en) Compositions and methods for treating pterygium
KR20260046518A (ko) 익상편을 치료하기 위한 조성물 및 방법
HK1256602B (en) Compositions and methods for treating pterygium
HK1253895B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601